Rossari Biotech Limited (NSE:ROSSARI)
India · Delayed Price · Currency is INR | Market Cap | 28.74B -22.3% |
| Revenue (ttm) | 23.96B +15.2% |
| Net Income | 1.49B +9.4% |
| EPS | 26.93 +9.3% |
| Shares Out | 55.39M |
| PE Ratio | 19.27 |
| Forward PE | 18.21 |
| Dividend | 0.50 (0.10%) |
| Ex-Dividend Date | Jun 20, 2025 |
| Volume | 60,438 |
| Open | 537.10 |
| Previous Close | 537.20 |
| Day's Range | 513.45 - 537.20 |
| 52-Week Range | 375.00 - 766.00 |
| Beta | 0.50 |
| Analysts | Buy |
| Price Target | 601.75 (+15.98%) |
| Earnings Date | Jul 17, 2026 |
About Rossari Biotech
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing li... [Read more]
Financial Performance
In fiscal year 2026, Rossari Biotech's revenue was 23.96 billion, an increase of 15.19% compared to the previous year's 20.80 billion. Earnings were 1.49 billion, an increase of 9.41%.
Financial StatementsNews
Rossari Biotech Transcript: Q4 25/26
Q4 and FY 2026 saw record revenue and EBITDA, with 15% annual growth driven by all segments and strong exports. FY 2027 guidance targets similar or higher growth and 12%-13% EBITDA margins, supported by new capacities, product mix improvements, and cost optimization.
Rossari Biotech Quarterly report: Q4 2026
Rossari Biotech has published its Q4 2026 quarterly earnings report on April 28, 2026.
Rossari Biotech Slides: Q4 2026
Rossari Biotech has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 28, 2026.
Rossari Biotech subsidiary approves Rs 10 crore sale of Mumbai office premises
Rossari Biotech's material subsidiary, Unitop Chemicals Private Limited, has approved the sale of its office premises located in Saki Naka, Mumbai. The transaction, valued at approximately ₹10 crores,...
Rossari Biotech Transcript: Q3 25/26
Q3 FY26 saw 13% YoY revenue growth, led by strong export performance and broad-based segment gains, though margins were impacted by ongoing investments and B2C weakness. New capacities and global expansion, especially in Saudi Arabia, are set to drive future growth and margin improvement.
Rossari Biotech Quarterly report: Q3 2026
Rossari Biotech has published its Q3 2026 quarterly earnings report on January 19, 2026.
Rossari Biotech Slides: Q3 2026
Rossari Biotech has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 19, 2026.
Rossari Biotech Transcript: Q2 25/26
Q2 FY 2026 saw 18% revenue growth, led by strong volumes across all core segments and robust export gains, though margins softened due to pricing pressures and one-time expenses. Capacity expansions and new product launches support a positive outlook, but global tariffs and working capital stretch pose risks.
Rossari Biotech Quarterly report: Q2 2026
Rossari Biotech has published its Q2 2026 quarterly earnings report on October 17, 2025.
Rossari Biotech Slides: Q2 2026
Rossari Biotech has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 17, 2025.
Rossari Biotech Transcript: Q1 25/26
Q1 FY26 saw 11% YoY revenue growth, led by HPPC and AHN, with EBITDA margin at 12.5%. Capacity expansions and international initiatives are underway, with mid-double-digit growth and margin improvement expected as new facilities ramp up and export headwinds ease.
Rossari Biotech Quarterly report: Q1 2026
Rossari Biotech has published its Q1 2026 quarterly earnings report on July 21, 2025.
Rossari Biotech Slides: Q1 2026
Rossari Biotech has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on July 21, 2025.
Rossari Biotech’s subsidiary wins GST appeal; previous tax order set aside
Rossari Biotech Limited has announced that its subsidiary, Unitop Chemicals Private Limited, has successfully won an appeal against a GST Order issued by the Joint Commissioner, Central GST & Central ...
Rossari Biotech stock drops 4.28% following Q2 results
Rossari Biotech saw its stock price fall by 4.28%, trading at ₹838.35 as of 9:35 AM today. The drop follows the company’s release of its Q2 FY24-25 earnings, which failed to meet market expectations. ...